[HTML][HTML] Nirsevimab for prevention of hospitalizations due to RSV in infants
SB Drysdale, K Cathie, F Flamein, M Knuf…�- …�England Journal of�…, 2023 - Mass Medical Soc
Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract�…
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract�…
[HTML][HTML] Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on�…
JM Jones�- MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…
Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling�…
M Del Riccio, P Spreeuwenberg, R Osei-Yeboah…�- medRxiv, 2023 - medrxiv.org
Background Respiratory syncytial virus (RSV) infections cause an estimated 22-50 million
episodes of acute lower respiratory infections (ALRI) every year in children younger than 5�…
episodes of acute lower respiratory infections (ALRI) every year in children younger than 5�…
The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness
DR Feikin, RA Karron, SK Saha, E Sparrow…�- The Lancet Infectious�…, 2024 - thelancet.com
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness and death
among children worldwide, particularly in children younger than 6 months and in low�…
among children worldwide, particularly in children younger than 6 months and in low�…
[HTML][HTML] Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First�…
HL Moline�- MMWR. Morbidity and mortality weekly report, 2024 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the
United States. In August 2023, CDC's Advisory Committee on Immunization Practices�…
United States. In August 2023, CDC's Advisory Committee on Immunization Practices�…
Infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak
Importance Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract
infections (LRTIs) and infant hospitalization worldwide. Objective To evaluate the�…
infections (LRTIs) and infant hospitalization worldwide. Objective To evaluate the�…
Burden of respiratory syncytial virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years
M Del Riccio, P Spreeuwenberg…�- The Journal of�…, 2023 - academic.oup.com
Background No overall estimate of respiratory syncytial virus (RSV)-associated
hospitalizations in children aged under 5 years has been published for the European Union�…
hospitalizations in children aged under 5 years has been published for the European Union�…
Pediatric RSV-associated hospitalizations before and during the COVID-19 pandemic
M Bourdeau, NK Vadlamudi, N Bastien…�- JAMA Network�…, 2023 - jamanetwork.com
Importance Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalizations.
Objective To describe the epidemiology and burden of RSV-associated hospitalizations�…
Objective To describe the epidemiology and burden of RSV-associated hospitalizations�…
[HTML][HTML] Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus–associated lower respiratory tract�…
KE Fleming-Dutra�- MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV�…
Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV�…
Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: a retrospective cohort study of a health system
Background Surveillance in 2020–2021 showed that seasonal respiratory illnesses were
below levels seen during prior seasons, with the exception of interseasonal respiratory�…
below levels seen during prior seasons, with the exception of interseasonal respiratory�…